Moleculin Biotech: amends 2024 equity plan to add 3,861,894 shares

What happened Moleculin Biotech, Inc. reported that it held its scheduled 2026 Annual Meeting of Stockholders on Oct 9, 2026, at which the Company’s stockholders approved amendments to the Company's 2024 Equity Plan (the “2024 Plan”), including an increase in the number of shares of common stock authorized for issuance under the 2024 Plan by 3,861,894 shares. As amended, the number of shares of common stock that may be issued under the 2024 Plan is 3,875,999 shares. The filing references the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on Aug 24, 2026.

Key details

• Annual Meeting held on Oct 9, 2026.
• Approved increase of 3,861,894 shares under the 2024 Plan.
• New total authorized under the 2024 Plan is 3,875,999 shares.
• The filing incorporates by reference the Proxy Statement filed Aug 24, 2026 and states the amended 2024 Plan is filed as Exhibit 10.1.

Why it may matter

• Item 5.07 (submission of matters to a vote of security holders) reports the stockholder approval described above, which amends the 2024 Equity Plan's authorized share amount.
• Item 5.02 (departure of directors or certain officers; election of directors) is listed in the filing but contains only the text: "As reported below under".

A filing does not show why the insider traded or why the company acted.